32 Jurisdictional Agility: Adapting to global differences in SPC calculations and the looming 2026 patent cliff in China and other middle-income markets
Semaglutide targets the GLP-1 receptor, Tirzepatide activates both GLP-1 and GIP receptors, and Retatrutide is an investigational triple-action peptide that targets GLP-1, GIP, and glucagon receptors
Weight loss is the key driver for these effects
Unlike prescription GLP-1 medications where discontinuation can trigger noticeable withdrawal symptoms and appetite rebound, stopping resM is unlikely to produce dramatic changes
However, the insulin sensitivity of the recipients and the composition of their gut microbiota returned to baseline after 18 weeks post-intervention (Kootte et al., 2017)
Supplementary information Supplementary Figures and Tables (PDF 594 kb) PowerPoint slides Rights and permissions About this article Cite this article Muskiet, M., Tonneijck, L., Smits, M